Why Is Poor Drug Solubility Such a Challenge?
Many drug candidates have limited water solubility. For these compounds, simply increasing the dose does not necessarily solve the formulation problem. The drug must first dissolve in the relevant biological environment before it can become available for absorption.
Poor solubility can therefore create challenges involving dissolution rate, formulation development and bioavailability. Recent pharmaceutical research continues to investigate cyclodextrins as excipients capable of improving the physicochemical performance of poorly soluble drugs. (PubMed)
How Does Cyclodextrin Inclusion Work?
The molecular structure of cyclodextrins is central to their function.
A cyclodextrin molecule has a hydrophilic exterior and a relatively hydrophobic cavity. When a suitable drug molecule interacts with the cavity, part or all of the hydrophobic portion of the drug can become accommodated inside the cyclodextrin.
This process is known as inclusion complex formation.
Importantly, this is generally a non-covalent interaction rather than a chemical reaction. The drug and cyclodextrin can interact through forces such as hydrophobic interactions, hydrogen bonding and van der Waals interactions.
The resulting inclusion complex can modify several physicochemical properties of the drug, including apparent aqueous solubility and dissolution behavior. (PubMed)
From "Poorly Soluble" to "More Formulatable"
One of the most important pharmaceutical applications of cyclodextrins is solubility enhancement.
When an appropriate drug forms an inclusion complex with a cyclodextrin, the hydrophilic exterior of the cyclodextrin can help the drug–cyclodextrin complex interact with the aqueous environment.
As a result, the apparent solubility of certain poorly water-soluble drugs may increase.
Different cyclodextrins can provide different formulation characteristics. Natural cyclodextrins such as α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin have different cavity sizes, while derivatives such as hydroxypropyl-β-cyclodextrin (HP-β-CD) and sulfobutyl ether-β-cyclodextrin sodium (SBE-β-CD) have been developed to provide modified physicochemical properties and pharmaceutical functionality. (PubMed)
Cyclodextrins Can Also Support Drug Stability
Solubility is only one part of the formulation challenge.
Some active pharmaceutical ingredients are sensitive to environmental factors such as oxidation, hydrolysis or light. Inclusion complexation can change the microenvironment surrounding a drug molecule and may help protect susceptible molecules under appropriate formulation conditions.
Research has reported that cyclodextrin inclusion complexes can improve the physical and chemical stability of certain drugs, although the effect depends strongly on the specific drug, cyclodextrin, formulation conditions and type of interaction involved. (PubMed)
Therefore, cyclodextrin should not be viewed simply as a "solubility enhancer." Its role can extend to improving the overall physicochemical performance of a pharmaceutical formulation.
Why Is the Choice of Cyclodextrin Important?
Not every cyclodextrin is suitable for every drug.
The size and characteristics of the drug molecule need to be considered together with the cavity size, physicochemical properties and intended dosage form of the cyclodextrin.
For example, β-cyclodextrin has a cavity size suitable for many small and medium-sized hydrophobic molecules, while modified derivatives such as HP-β-CD and SBE-β-CD can offer different solubility and formulation characteristics.
The final selection should therefore be based on factors such as:
* Drug molecular size and structure
* Drug–cyclodextrin complexation efficiency
* Target solubility enhancement
* Dosage form
* Route of administration
* Required stability
* Safety and regulatory requirements
* Compatibility with other formulation excipients
A Growing Role in Modern Drug Delivery
Cyclodextrin technology is now being investigated beyond conventional solubility enhancement.
Recent research has explored cyclodextrin-based systems for oral, ophthalmic, topical and parenteral formulations, as well as controlled-release and more advanced drug-delivery systems. (PubMed)
A 2026 review in AAPS PharmSciTech also highlights the continuing development of cyclodextrins as multifunctional pharmaceutical excipients, including their roles in improving drug solubility, stability, dissolution and biopharmaceutical performance. (PubMed)
Conclusion
For poorly water-soluble drugs, formulation development can be a complex challenge. Cyclodextrin inclusion technology offers a molecular-level approach by forming non-covalent inclusion complexes with suitable drug molecules.
Through this mechanism, cyclodextrins can improve the apparent aqueous solubility and dissolution behavior of certain drugs while potentially contributing to physical and chemical stability.
As pharmaceutical development continues to focus on poorly soluble APIs and more sophisticated drug-delivery systems, cyclodextrins and their derivatives remain an important area of formulation research.
